

## “Solution space” status: 2003

Donors/  
Countries  
Willing to  
Finance

- No financing committed to pneumococcal vaccine purchase
- Too expensive to manufacture/Never affordable


Industry  
Willing to  
Supply

- Supply limited to just enough for rich countries
- Vaccines \$60/dose; doesn't include serotypes or vial sizes countries want


Countries  
Willing to  
Introduce

- No WHO recommendation
- No WHO disease burden estimates by country

# Saving lives requires finding “solution space” for 3 main stakeholders



# GAVI's pneumoADIP



## Strengths of the process & analysis

- Transparent assumptions
- A lot of stakeholder input and communication
- Data analyses customized to provide outputs meaningful to each stakeholder
- Engaged a variety of stakeholders to build political support



All-Party Parliamentary Group on Pneumococcal  
Disease Prevention in the Developing World



## “Solution space” status: 2010

Donors/  
Countries  
Willing to  
Finance

- Pneumococcal AMC launched
- \$1.5 billion from 6 donors + up to \$1.3B from GAVI

Industry  
Willing to  
Supply


- Four multinational and emerging manufacturers have responded to a call for offers to supply GAVI countries
- Vaccines will have high serotype coverage, affordable price, and good vial size

Countries  
Willing to  
Introduce

- WHO recommends pneumococcal vaccine in routine immunization programs
- 13 approvals, 12 awaiting approval/conditional approval/clarification

# Progress can be measured in deaths averted

**2008 vs. inaction = 5.08 million deaths averted**  
**2008 vs. 2006 = 1.38 deaths averted**



Thank you!



For more information on pneumococcal disease or the vaccines, please visit

[www.preventpneumo.org](http://www.preventpneumo.org)

[www.jhsph.edu/ivac](http://www.jhsph.edu/ivac)

[www.sabin.org/PACE](http://www.sabin.org/PACE)

[www.worldpneumoniaday.org](http://www.worldpneumoniaday.org)